- Home
- CCCC vs TWN Comparison
CCCC vs TWN Comparison
Compare CCCC & TWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- TWN
- Stock Information
- Founded
- CCCC 2015
- TWN 1986
- Country
- CCCC United States
- TWN Hong Kong
- Employees
- CCCC N/A
- TWN N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- TWN Trusts Except Educational Religious and Charitable
- Sector
- CCCC Health Care
- TWN Finance
- Exchange
- CCCC Nasdaq
- TWN Nasdaq
- Market Cap
- CCCC 104.4M
- TWN 285.6M
- IPO Year
- CCCC 2020
- TWN N/A
- Fundamental
- Price
- CCCC $2.26
- TWN $45.55
- Analyst Decision
- CCCC Buy
- TWN
- Analyst Count
- CCCC 3
- TWN 0
- Target Price
- CCCC $12.00
- TWN N/A
- AVG Volume (30 Days)
- CCCC 1.6M
- TWN 20.1K
- Earning Date
- CCCC 07-31-2025
- TWN 01-01-0001
- Dividend Yield
- CCCC N/A
- TWN 1.10%
- EPS Growth
- CCCC N/A
- TWN N/A
- EPS
- CCCC N/A
- TWN N/A
- Revenue
- CCCC $39,783,000.00
- TWN N/A
- Revenue This Year
- CCCC N/A
- TWN N/A
- Revenue Next Year
- CCCC N/A
- TWN N/A
- P/E Ratio
- CCCC N/A
- TWN N/A
- Revenue Growth
- CCCC 98.56
- TWN N/A
- 52 Week Low
- CCCC $1.09
- TWN $25.22
- 52 Week High
- CCCC $7.66
- TWN $41.51
- Technical
- Relative Strength Index (RSI)
- CCCC 63.62
- TWN 73.71
- Support Level
- CCCC $1.36
- TWN $44.47
- Resistance Level
- CCCC $2.17
- TWN $45.91
- Average True Range (ATR)
- CCCC 0.15
- TWN 0.51
- MACD
- CCCC 0.05
- TWN -0.15
- Stochastic Oscillator
- CCCC 67.11
- TWN 90.37
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About TWN Taiwan Fund Inc. (The)
Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.